Great Ormond Street Hospital for Children, London, UK.
Heart. 2010 Sep;96(17):1401-6. doi: 10.1136/hrt.2009.182378. Epub 2010 Apr 20.
To clarify the clinical characteristics and epidemiology of idiopathic pulmonary arterial hypertension (IPAH) in childhood, a rare condition with a bad prognosis, poorly documented in children. Also, to describe the long-term outcome.
A retrospective study of 7 years' experience.
UK Service for Pulmonary Hypertension in Children based at a tertiary referral centre.
64 children.
Patients were initially treated with prostanoids (n=15), bosentan (n=23), sildenafil (n=9), combination therapy (n=11) or calcium channel antagonists (n=6).
WHO functional class, distance walked in 6 minutes, escalation of therapy, survival, transplant-free survival.
Incidence of IPAH was 0.48 cases per million children per year and the prevalence was 2.1 cases per million. 31% presented with syncope. Oedema was rare. During the first year of follow-up WHO functional class and 6-minute walk distance improved significantly. Survival at 1, 3 and 5 years was 89%, 84% and 75%, respectively; while transplant-free survival was 89% 76% and 57%, respectively. Factors predicting worse survival were WHO functional class (HR 2.4, p=0.04) and poor height and weight z-score (p<0.05 for both) at presentation.
We showed, for the first time, that the incidence of IPAH is lower in children than adults and that the clinical features can be different. Most children present with clinical evidence of advanced disease and clinical status at presentation is predictive of outcome. This 7-year experience confirms the significant improvement in survival over historical controls.
阐明儿童特发性肺动脉高压(IPAH)的临床特征和流行病学,这种疾病预后不良,在儿童中记录较少。同时,描述长期预后。
回顾性研究,经验 7 年。
英国儿童肺动脉高压服务机构,位于三级转诊中心。
64 名儿童。
患者最初接受前列环素(n=15)、波生坦(n=23)、西地那非(n=9)、联合治疗(n=11)或钙通道拮抗剂(n=6)治疗。
WHO 功能分级、6 分钟步行距离、治疗升级、生存、无移植生存。
IPAH 的发病率为每百万儿童每年 0.48 例,患病率为每百万儿童 2.1 例。31%的患者出现晕厥。水肿少见。在随访的第一年,WHO 功能分级和 6 分钟步行距离显著改善。1、3 和 5 年生存率分别为 89%、84%和 75%;无移植生存率分别为 89%、76%和 57%。预测生存率较差的因素是 WHO 功能分级(HR 2.4,p=0.04)和较差的身高和体重 z 评分(p<0.05)。
我们首次表明,儿童 IPAH 的发病率低于成人,且临床特征可能不同。大多数儿童出现晚期疾病的临床证据,且就诊时的临床状况可预测预后。这 7 年的经验证实了生存率较历史对照有显著提高。